KRas and the homologous NRas and HRas are mutated in 10–30% of all cancers.[30] Mutations in Ras proteins lead to their continuous activation by stabilizing the so‐called “switch” regions in the protein in their active conformation. The gene discussed is KRAS; the disease is cancer.